Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 36Neoplasm Metastasis 8Ovarian Neoplasms 5Sarcoma 4Neoplasms 4Lymphoma, Non-Hodgkin 4Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Glioma 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Liposarcoma 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1palbociclib 1erdafitinib 1X-Rays 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Diffusion Tensor Imaging 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial ependymoma × palbociclib × 90 days × Clear all
NCT03526250 2026-04-03

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 11 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡